Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans - Implications for the evaluation of transporter-mediated flavonoid-drug interactions

European Journal of Pharmaceutical Sciences

Volumn 61, Issue 1, 2014, Pages 54-60

  Nguyen, M A ^a   Staubach, P ^b   Wolffram, S ^c   Langguth, P ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

Flavonoid; Interaction; OATP; P glycoprotein; Quercetin; Talinolol

Indexed keywords

FLAVONOID; FLAVONOL DERIVATIVE; ISORHAMNETIN; KAEMPFEROL; ORGANIC ANION TRANSPORTER; QUERCETIN; RHAMNETIN; TALINOLOL; MULTIDRUG RESISTANCE PROTEIN; PROPANOLAMINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; URINALYSIS; URINARY EXCRETION; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG INTERACTION; INTESTINE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TRANSPORT AT THE CELLULAR LEVEL; URINE; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL TRANSPORT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INTESTINES; MALE; MIDDLE AGED; P-GLYCOPROTEINS; PROPANOLAMINES; QUERCETIN; YOUNG ADULT;

EID: 84902535386     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2014.01.003     Document Type: Article

References (48)

1. R.M. Aurade, S.M. Akbar, H. Goud, S.K. Jayalakshmi, and K. Sreeramulu Inhibition of p-glycoprotein atpase and its transport function of helicoverpa armigera by morin, quercetin and phloroglucinol Pestic. Biochem. Phys. 101 2011 212 219
2. K. Azuma, K. Ippoushi, H. Ito, H. Higashio, and J. Terao Combination of lipids and emulsifiers enhances the absorption of orally administered quercetin in rats J. Agric. Food Chem. 50 2002 1706 1712 (Pubitemid 34233251)
3. T. Bansal, A. Awasthi, M. Jaggi, R.K. Khar, and S. Talegaonkar Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (cpt-11) in combination with quercetin: possible contribution of p-glycoprotein Life Sci. 83 2008 250 259
4. A. Bernsdorf, T. Giessmann, C. Modess, D. Wegner, S. Igelbrink, U. Hecker, S. Haenisch, I. Cascorbi, B. Terhaag, and W. Siegmund Simvastatin does not influence the intestinal p-glycoprotein and mpr2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the abcb1, abcc2 and slco1b1 polymorphisms Brit. J. Clin. Pharmacol. 61 2006 440 450
5. I. Boomgaarden, S. Egert, G. Rimbach, S. Wolffram, M.J. Muller, and F. Doring Quercetin supplementation and its effect on human monocyte gene expression profiles in vivo Brit. J. Nutr. 104 2010 336 345
6. W. Brand, M.E. Schutte, G. Williamson, J.J. van Zanden, N.H.P. Cnubben, J.P. Groten, P.J. van Bladeren, and I. Rietjens Flavonoid-mediated inhibition of intestinal abc transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients Biomed. Pharmacother. 60 2006 508 519 (Pubitemid 44635082)
7. R. Cermak Effect of dietary flavonoids on pathways involved in drug metabolism Exp. Opin. Drug Met. 4 2008 17 35 (Pubitemid 351234098)
8. M.N. Chabane, A. Al Ahmad, J. Peluso, C.D. Muller, and G. Ubeaud Quercetin and naringenin transport across human intestinal caco-2 cells J. Pharm. Pharmacol. 61 2009 1473 1483
9. J.S. Choi, B.W. Jo, and Y.C. Kim Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin Eur. J. Pharm. Biopharm. 57 2004 313 318
10. G. Conseil, H. Baubichon-Cortay, G. Dayan, J.M. Jault, D. Barron, and A. Di Pietro Flavonoids: a class of modulators with bifunctional interactions at vicinal atp- and steroid-binding sites on mouse p-glycoprotein P. Natl. Acad. Sci. USA 95 1998 9831 9836
11. R. DiCenzo, V. Frerichs, P. Larppanichpoonphol, L. Predko, A. Chen, R. Reichman, and M. Morris Effect of quercetin on the plasma and intracellular concentrations of saquinavir in healthy adults Pharmacotherapy 26 2006 1255 1261 (Pubitemid 44306885)
12. S. Egert, S. Wolffram, A. Bosy-Westphal, C. Boesch-Saadatmandi, A.E. Wagner, J. Frank, G. Rimbach, and M.J. Mueller Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans J. Nutr. 138 2008 1615 1621
13. S. Egert, A. Bosy-Westphal, J. Seiberl, C. Kurbitz, U. Settler, S. Plachta-Danielzik, A.E. Wagner, J. Frank, J. Schrezenmeir, G. Rimbach, S. Wolffram, and M.J. Muller Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study Brit. J. Nutr. 102 2009 1065 1074
14. S. Egert, S. Wolffram, B. Schulze, P. Langguth, E.M. Hubbermann, K. Schwarz, B. Adolphi, A. Bosy-Westphal, G. Rimbach, and M.J. Muller Enriched cereal bars are more effective in increasing plasma quercetin compared with quercetin from powder-filled hard capsules Brit. J. Nutr. 107 2012 539 546
15. I. Erlund, T. Kosonen, G. Alfthan, J. Maenpaa, K. Perttunen, J. Kenraali, J. Parantainen, and A. Aro Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers Eur. J. Clin. Pharmacol. 56 2000 545 553
16. D.R. Ferry, A. Smith, J. Malkhandi, D.W. Fyfe, P.G. deTakats, D. Anderson, J. Baker, and D.J. Kerr Phase i clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition Clin. Cancer Res. 2 1996 659 668 (Pubitemid 26133468)
17. A. Ghosh, A.K. Mandal, S. Sarkar, S. Panda, and N. Das Nanoencapsulation of quercetin enhances its dietary efficacy in combating arsenic-induced oxidative damage in liver and brain of rats Life Sci. 84 2009 75 80
18. M. Harwood, B. Danielewska-Nikiel, J.F. Borzelleca, G.W. Flamm, G.M. Williams, and T.C. Lines A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcino genic properties Food Chem. Toxicol. 45 2007 2179 2205 (Pubitemid 47451573)
19. S.L. Hsiu, Y.C. Hou, Y.H. Wang, C.W. Tsao, S.F. Su, and P.D.L. Chao Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats Life Sci. 72 2002 227 235
20. F. Jin, D.C. Nieman, R.A. Shanely, A.M. Knab, M.D. Austin, and W. Sha The variable plasma quercetin response to 12-week quercetin supplementation in humans Eur. J. Clin. Nutr. 64 2010 692 697
21. K.A. Kim, P.W. Park, and J.Y. Park Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of p-glycoprotein, in healthy volunteers Eur. J. Clin. Pharmacol. 65 2009 609 614
22. D. Kobayashi, T. Nozawa, K. Imai, J.I. Nezu, A. Tsuji, and I. Tamai Involvement of human organic anion transporting polypeptide oatp-b (slc21a9) in ph-dependent transport across intestinal apical membrane J. Pharmacol. Exp. Ther. 306 2003 703 708 (Pubitemid 36886171)
23. G. Leonarduzzi, G. Testa, B. Sottero, P. Gamba, and G. Poli Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids Curr. Med. Chem. 17 2010 74 95
24. S. Lesser, and S. Wolffram Oral bioavailability of the flavonol quercetin - a review Curr. Top. Nutraceut. R 4 2006 239 256 (Pubitemid 46584530)
25. Y. Li, and J.W. Paxton The effects of flavonoids on the abc transporters: consequences for the pharmacokinetics of substrate drugs Exp. Opin. Drug Met. 9 2013 267 285
26. K. Mandery, K. Bujok, I. Schmidt, M. Keiser, W. Siegmund, B. Balk, J. Konig, M.F. Fromm, and H. Glaeser Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1a2 and 2b1 Biochem. Pharmacol. 80 2010 1746 1753
27. Y. Mitsunaga, H. Takanaga, H. Matsuo, M. Naito, T. Tsuruo, H. Ohtani, and Y. Sawada Effect of bioflavonoids on vincristine transport across blood-brain barrier Eur. J. Pharmacol. 395 2000 193 201 (Pubitemid 30254368)
28. Y.J. Moon, L. Wang, R. DiCenzo, and M.E. Morris Quercetin pharmacokinetics in humans Biopharmaceut. Drug Dispos. 29 2008 205 217 (Pubitemid 351802843)
29. F. Naddaf, M. Keiser, K. Didrigkeit, S. Oswald, E. Scheuch, K. Kock, H.K. Kroemer, and W. Siegmund In vitro effects of intestinal and hepatic uptake transporters on talinolol uptake Brit. J. Clin. Pharmacol. 70 2010 45
30. T. Nozawa, K. Imai, J.I. Nezu, A. Tsuji, and I. Tamai Functional characterization of ph-sensitive organic anion transporting polypeptide oatp-b in human J. Pharmacol. Exp. Ther. 308 2004 438 445 (Pubitemid 38134202)
31. M. Ofer, S. Wolffram, A. Koggel, H. Spahn-Langguth, and P. Langguth Modulation of drug transport by selected flavonoids: involvement of p-gp and oct? Eur. J. Pharm. Sci. 25 2005 263 271 (Pubitemid 40725056)
32. S. Oswald, B. Terhaag, and W. Siegmund In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal p-glycoprotein (abcb1) in humans M.F. Fromm, R.B. Kim, Drug Transporters 2011 Springer Berlin Heidelberg 403 447
33. H.S. Park, J.H. Oh, J.H. Lee, and Y.J. Lee Minor effects of the citrus flavonoids naringin, naringenin and quercetin, on the pharmacokinetics of doxorubicin in rats Pharmazie 66 2011 424 429
34. J. Perez-Jimenez, L. Fezeu, M. Touvier, N. Arnault, C. Manach, S. Hercberg, P. Galan, and A. Scalbert Dietary intake of 337 polyphenols in french adults Am. J. Clin. Nutr. 93 2011 1220 1228
35. A.B. Shapiro, and V. Ling Effect of quercetin on hoechst 33342 transport by purified and reconstituted p-glycoprotein Biochem. Pharmacol. 53 1997 587 596 (Pubitemid 27149553)
36. Y. Shirasaka, E. Kuraoka, H. Spahn-Langguth, T. Nakanishi, P. Langguth, and I. Tamai Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat J. Pharmacol. Exp. Ther. 332 2010 181 189
37. Y. Shirasaka, M. Shichiri, T. Mori, T. Nakanishi, and I. Tamai Major active components in grapefruit, orange, and apple juices responsible for oatp2b1-mediated drug interactions J. Pharmaceut. Sci. 102 2013 280 288
38. H. Spahn-Langguth, G. Baktir, A. Radschuweit, A. Okyar, B. Terhaag, P. Ader, A. Hanafy, and P. Langguth P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound Int. J. Clin. Pharmacol. Therap. 36 1998 16 24 (Pubitemid 28031804)
39. J.V. St Peter, M. Pirner, R.C. Brundage, and T.S. Tracy Co-administration of quercetin and digoxin: evaluation of potential nutrient-drug interaction involving the p-glycoprotein transporter Clin. Pharmacol. Ther. 89 2011 S22-S22
40. I. Tamai Oral drug delivery utilizing intestinal oatp transporters Adv. Drug Deliv. Rev. 64 2012 508 514
41. B. Trausch, R. Oertel, K. Richter, and T. Gramatte Disposition and bioavailability of the beta(1)-adrenoceptor antagonist talinolol in man Biopharmaceut. Drug Dispos. 16 1995 403 414
42. M.D. Troutman, and D.R. Thakker Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by p-glycoprotein in cell culture models of intestinal epithelium Pharmaceut. Res. 20 2003 1210 1224 (Pubitemid 36951846)
43. M. Tubic, D. Wagner, H. Spahn-Langguth, C. Weiler, R. Wanitschke, W.O. Bocher, and P. Langguth Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans Eur. J. Pharm. Sci. 29 2006 231 239 (Pubitemid 44602403)
44. Y.H. Wang, P.D.L. Chao, S.L. Hsiu, K.C. Wen, and Y.C. Hou Lethal quercetin-digoxin interaction in pigs Life Sci. 74 2004 1191 1197
45. S. Wein, and S. Wolffram Oral bioavailability of quercetin in horses J. Equine Vet. Sci. 33 2013 441 445
46. U. Wetterich, H. SpahnLangguth, E. Mutschler, B. Terhaag, W. Rosch, and P. Langguth Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo Pharmaceut. Res. 13 1996 514 522 (Pubitemid 26119052)
47. C.P. Yu, P.P. Wu, Y.C. Hou, S.P. Lin, S.Y. Tsai, C.T. Chen, and P.D.L. Chao Quercetin and rutin reduced the bioavailability of cyclosporine from neoral, an immunosuppressant, through activating p-glycoprotein and cyp 3a4 J. Agric. Food Chem. 59 2011 4644 4648
48. Z.P. Yuan, L.J. Chen, L.Y. Fan, M.H. Tang, G.L. Yang, H.S. Yang, X.B. Du, G.Q. Wang, W.X. Yao, Q.M. Zhao, B. Ye, R. Wang, P. Diao, W. Zhang, H.B. Wu, X. Zhao, and Y.Q. Wei Liposomal quercetin efficiently suppresses growth of solid tumors in murine models Clin. Cancer Res. 12 2006 3193 3199 (Pubitemid 43837369)